GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » Arcadia Biosciences Inc (NAS:RKDA) » Definitions » Return-on-Tangible-Equity

RKDA (Arcadia Biosciences) Return-on-Tangible-Equity : -58.85% (As of Sep. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Arcadia Biosciences Return-on-Tangible-Equity?

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Arcadia Biosciences's annualized net income for the quarter that ended in Sep. 2024 was $-6.45 Mil. Arcadia Biosciences's average shareholder tangible equity for the quarter that ended in Sep. 2024 was $10.96 Mil. Therefore, Arcadia Biosciences's annualized Return-on-Tangible-Equity for the quarter that ended in Sep. 2024 was -58.85%.

The historical rank and industry rank for Arcadia Biosciences's Return-on-Tangible-Equity or its related term are showing as below:

RKDA' s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -280.75   Med: -72.81   Max: -26.87
Current: -47.92

During the past 12 years, Arcadia Biosciences's highest Return-on-Tangible-Equity was -26.87%. The lowest was -280.75%. And the median was -72.81%.

RKDA's Return-on-Tangible-Equity is ranked worse than
94.64% of 1811 companies
in the Consumer Packaged Goods industry
Industry Median: 8.05 vs RKDA: -47.92

Arcadia Biosciences Return-on-Tangible-Equity Historical Data

The historical data trend for Arcadia Biosciences's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arcadia Biosciences Return-on-Tangible-Equity Chart

Arcadia Biosciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Return-on-Tangible-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only -280.75 -26.87 -50.94 -59.59 -82.74

Arcadia Biosciences Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -61.63 -80.66 -82.89 38.15 -58.85

Competitive Comparison of Arcadia Biosciences's Return-on-Tangible-Equity

For the Packaged Foods subindustry, Arcadia Biosciences's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Arcadia Biosciences's Return-on-Tangible-Equity Distribution in the Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, Arcadia Biosciences's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where Arcadia Biosciences's Return-on-Tangible-Equity falls into.



Arcadia Biosciences Return-on-Tangible-Equity Calculation

Arcadia Biosciences's annualized Return-on-Tangible-Equity for the fiscal year that ended in Dec. 2023 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=-13.981/( (20.993+12.802 )/ 2 )
=-13.981/16.8975
=-82.74 %

Arcadia Biosciences's annualized Return-on-Tangible-Equity for the quarter that ended in Sep. 2024 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Sep. 2024 )  (Q: Jun. 2024 )(Q: Sep. 2024 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Sep. 2024 )  (Q: Jun. 2024 )(Q: Sep. 2024 )
=-6.448/( (11.665+10.248)/ 2 )
=-6.448/10.9565
=-58.85 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Sep. 2024) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


Arcadia Biosciences  (NAS:RKDA) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


Arcadia Biosciences Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of Arcadia Biosciences's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Arcadia Biosciences Business Description

Traded in Other Exchanges
Address
5950 Sherry Lane, Suite 215, Dallas, TX, USA, 75225
Arcadia Biosciences Inc is a producer and marketer of plant-based food and beverage products. It is engaged in science-based approaches to developing high-value crop improvements in wheat, soy, and hemp, designed to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients, health, and wellness products, and their viability for industrial applications. The company's consumer brands in the food, beverage, and body care categories include GoodWheat high-fiber pasta, Zola coconut water and others.
Executives
Thomas J. Schaefer officer: Chief Financial Officer 202 COUSTEAU PLACE STE 105, DAVIS CA 95618
Stanley Jr Jacot officer: Chief Executive Officer 202 COUSTEAU PLACE STE 105, DAVIS CA 95618
Pamela Haley officer: Chief Financial Officer 202 COUSTEAU PLACE, DAVIS CA 95618
Laura Pitlik officer: Chief Marketing Officer 202 COUSTEAU PLACE, SUITE 105, DAVIS CA 95618
Chris Cuvelier officer: Chief Growth Officer 202 COUSTEAU PLACE, SUITE 105, DAVIS CA 95618
Deborah D Carosella director 3603 HAVEN AVE, SUITE E, MENLO PARK CA 94025
Matthew T Plavan officer: Chief Financial Officer C/O THERMOGENESIS CORP., 2711 CITRUS ROAD, RANCHO CORDOVA CA 95742
Randall Shultz officer: Chief Technology Officer 4222 E. THOMAS ROAD, SUITE 320, PHOEBIIX AZ 85018
Sarah Reiter officer: Chief Commercial Officer 202 COUSTEAU PLACE, DAVIS CA 95618
Lilian Shackelford Murray director 228 BEACH ROAD, BELVEDERE CA 94920
Kevin Comcowich director C/O ARCADIA BIOSCIENCES, INC., 202 COUSTEAU PLACE, SUITE 105, DAVIS CA 95618
Albert D. Bolles director CONAGRA FOODS, INC., ONE CONAGRA DRIVE, MS 1-330, OMAHA NE 68102
Eric J. Rey director, officer: President and CEO ARCADIA BIOSCIENCES, INC., 202 COUSTEAU PLACE, SUITE 105, DAVIS CA 95618
Zhongjin Lu officer: VP Product Development ARCADIA BIOSCIENCES, INC., 202 COUSTEAU PLACE, SUITE 105, DAVIS CA 95618
Amy Yoder director C/O SPECTRUM BRANDS, INC., 6 CONCOURSE PARKWAY, SUITE 3300, ATLANTA GA 30328